why choose us

First received: May 10, 2023

Clinical Trial: Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face

Study Status: Completed

Recruit Status: RECRUITING

Condition: Actinic Keratosis

Study Type: INTERVENTIONAL


Official Title: Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face

Brief Summary: Interventional, monocentric, national, single-arm, uncontrolled, open, prospective phase IV study.Since this study is not powered for confirmative testing, analysis is done by descriptive statistics Eligible AK patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.Diagnosis and monitoring of treatment effects are supported by UV imaging using Canfield VISIA®.Safety and efficacy are assessed at end of treatment visit (EoT, approximately 3 days after the last dose, i.e,…

Read more